OncoMatch/Clinical Trials/NCT07192185
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Is NCT07192185 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including FOLFOX and Atezolizumab & Bevacizumab for hepatocellular carcinoma (hcc).
Treatment: FOLFOX · Atezolizumab & Bevacizumab — Atezolizumab plus bevacizumab is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, the effect of the second-line treatment after the progress of Atezolizumab plus bevacizumab therapy remains unsatisfactory. This is a prospective trial to investigate the efficacy and safety of systemic chemotherapy with FOLFOX plus Atezolizumab \& bevacizumab as second-line treatment for patients with advanced HCC who previously received atezolizumab plus bevacizumab
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-L1 therapy (atezolizumab) — first-line
Patients who have previously received first-line treatment with atezolizumab plus bevacizumab and who have shown tumor progression as confirmed by imaging studies.
Must have received: VEGF inhibitor (bevacizumab) — first-line
Patients who have previously received first-line treatment with atezolizumab plus bevacizumab and who have shown tumor progression as confirmed by imaging studies.
Cannot have received: systemic therapy
Exception: atezolizumab plus bevacizumab
No other systemic treatments have been administered.
Lab requirements
Blood counts
Hemoglobin ≥ 8.5 g/dL; Absolute neutrophil count (ANC) >1,500/mm3
Kidney function
Serum creatinine ≤ 1.5 x upper limit of normal
Liver function
Total bilirubin ≤ 30mmol/L; Serum albumin ≥ 30 g/L; ASL and AST ≤ 5 x upper limit of normal; INR ≤ 1.5 or PT/APTT within normal limits; No cirrhosis or cirrhotic status of Child-Pugh class A only
Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 30 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) >1,500/mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify